High KIT and PDGFRA are associated with shorter patients survival in gastroenteropancreatic neuroendocrine tumors, but mutations are a rare event

著录项

• 来源
  《Journal of Cancer Research and Clinical Oncology》 |2012年第3期|p.397-403|共7页
• 作者

  Thomas Knösel; Yuan Chen; Annelore Altendorf-Hofmann; Christine Danielczok; Martin Freesmeyer; Utz Settmacher; Christine Wurst; Stefan Schulz; Lin Lin Yang; Iver Petersen;

  展开▼
• 作者单位

  Institute of Pathology, Friedrich-Schiller University, Jena University Hospital, Ziegelmühlenweg 1, 07743, Jena, Germany;

  Institute of Pathology, Friedrich-Schiller University, Jena University Hospital, Ziegelmühlenweg 1, 07743, Jena, Germany;

  Department of General, Visceral and Vascular Surgery, Friedrich-Schiller University, Jena University Hospital, Jena, Germany;

  Institute of Pathology, Friedrich-Schiller University, Jena University Hospital, Ziegelmühlenweg 1, 07743, Jena, Germany;

  Department of Nuclear Medicine, Friedrich-Schiller University, Jena University Hospital, Jena, Germany;

  Department of General, Visceral and Vascular Surgery, Friedrich-Schiller University, Jena University Hospital, Jena, Germany;

  Department of General, Visceral and Vascular Surgery, Friedrich-Schiller University, Jena University Hospital, Jena, Germany;

  Department of Pharmacology, Friedrich-Schil;

  展开▼
• 收录信息
• 原文格式 PDF
• 正文语种 eng
• 中图分类
• 关键词

  Gastroenteropancreatic neuroendocrine tumors (GEP NETs); KIT; PDGFRA; Mutational analysis; Prognostic factor;

  机译：胃肠道胰腺神经内分泌肿瘤（GEP NETs）;KIT;PDGFRA;突变分析;预后因素;